Naramune-2 vaccine protects dogs against Canine Upper Respiratory Infection (Canine Cough) caused by Canine Parainfluenza and Bordetella bronchiseptica. The Canine Parainfluenza, modified live virus, B. bronchiseptica Vaccine, avirulent live culture, is designed to be administered intranasally for convenient, rapid prevention of Canine Upper Respiratory Infection. Both of these organisms are widespread, common etiologic agents of this syndrome which appears as a mild, self-limiting disease involving the trachea and bronchi of dogs of any age. It spreads rapidly among dogs that are closely confined as in hospitals, kennels and pet stores. Canine Cough is highly contagious and is transmitted by air. Naramune-2 is recommended for the vaccination of healthy dogs three weeks of age or older.
For intranasal vaccination of healthy dogs three weeks of age or older. Shake well before use.
25 (1 dose) vials of dry vaccine
25 (1 ml) vials of sterile vaccine diluent
25 single use nasal applicator tips
Contains Neomycin as a preservative.
Only vaccinate healthy animals. Animals incubating any disease or stressed due to shipping, malnutrition, or parasitism may not achieve or maintain an adequate immune response.
For intranasal use only. Do not vaccinate dogs parenterally.
In case of anaphylactoid reaction, administer epinephrine.
Store out of direct sunlight at 35°-45° F (2-7° C). Do not freeze. Use entire contents when first opened.
Burn vaccine containers and all unused contents.
Directions for Use: Rehydrate Naramune-2 to desired dose volume with accompanying sterile diluent. For one 1 ml dose, reconstitute with 1 ml of diluent. Shake well and use immediately. Using aseptic technique, administer entire dose intranasally. Use enclosed applicator tip on hub of syringe in place of syringe needle. Apply new nasal applicator tip for each dog vaccinated. Do not vaccinate puppies under 3 week of age. Puppies vaccinated between three and six weeks of age should be revaccinated at six weeks of age. Annual revaccination with one dose is recommended.
Both of the organisms in Naramune-2 are avirulent so that they can be safely administered intranasally with little or no symptoms of disease. By instilling these organisms into the nasal passages, it becomes possible for these agents to infect target cells of the nasal-pharyngeal region, mimicking the pathogenesis of natural field infection. A very small percentage of dogs may show sneezing, coughing or nasal discharge for 3-10 days following vaccination. While these are usually temporary symptoms, anti-bacterial therapy may be indicated.